Is Mounjaro approved for weight loss?
No, Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes management in adults, where it lowers blood sugar alongside diet and exercise.[1] Weight loss occurs as a common side effect due to slowed gastric emptying and appetite suppression, but it's not indicated solely for weight loss.
What about Zepbound, the weight loss version?
Eli Lilly markets tirzepatide as Zepbound specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like hypertension.[1] Zepbound uses the same active ingredient and dosing as Mounjaro but targets non-diabetic patients seeking ≥5% body weight reduction.
How much weight do patients lose on Mounjaro?
Clinical trials (SURMOUNT-1) showed average losses of 15-22% body weight over 72 weeks at higher doses (10-15mg weekly), outperforming semaglutide (Wegovy).[2] Real-world use for off-label weight loss reports similar results, though diabetes patients may lose less if insulin-resistant.
Why do doctors prescribe Mounjaro off-label for weight loss?
Shortages of approved obesity drugs like Wegovy have led to off-label Mounjaro prescriptions, as tirzepatide activates GLP-1 and GIP receptors for stronger effects than GLP-1-only drugs.[3] It's effective but risks insurance denial and side effects like nausea or pancreatitis.
What are common side effects during weight loss?
GI issues (nausea 20-30%, vomiting, diarrhea) peak early and fade; rarer risks include gallbladder disease, thyroid tumors (boxed warning), or muscle loss.[1][2] Patients report 10-20% dropout from tolerability.
How does Mounjaro compare to Ozempic or Wegovy for weight loss?
| Drug | Active Ingredient | Avg Weight Loss (72 weeks) | Primary Approval | Weekly Dose |
|------|-------------------|----------------------------|------------------|-------------|
| Mounjaro/Zepbound | Tirzepatide (GLP-1/GIP) | 15-22% | Diabetes/Obesity | 2.5-15mg |
| Ozempic/Wegovy | Semaglutide (GLP-1) | 12-15% | Diabetes/Obesity | 0.25-2.4mg |
Tirzepatide edges out semaglutide in head-to-head trials (SURMOUNT-2).[2]
Cost and access for weight loss
Mounjaro lists at $1,000+/month without insurance; savings cards cap at $25 for eligible patients.[4] Off-label use often lacks coverage—Zepbound may qualify for obesity. Compounded versions (post-shortage) cost $200-500/month but face FDA scrutiny for safety.
When does Mounjaro's patent expire?
Key U.S. patents on tirzepatide expire 2035-2036, with challenges possible earlier via litigation.[5] No biosimilars yet.
[1]: FDA.gov - Mounjaro/Zepbound labels (fda.gov/drugs)
[2]: NEJM - SURMOUNT trials (nejm.org/doi/full/10.1056/NEJMoa2206038)
[3]: Lilly.com - Mechanism (lilly.com/mounjaro)
[4]: GoodRx - Pricing (goodrx.com/mounjaro)
[5]: DrugPatentWatch.com - Tirzepatide patents (drugpatentwatch.com/p/trademark/MOUNJARO)